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Hodgkin’s Lymphoma was incurable until the advent of eﬀective therapeutic radiation around the ﬁrst half of the 20th century.
As survival rates improved, the long-term toxicities from radiotherapy began to emerge. This together with the availability of
eﬀective chemotherapy has encouraged a combined modality approach for early-staged disease and the omission of radiotherapy
in advanced-staged disease. The diﬀering toxicities of radiotherapy and chemotherapy has promoted ongoing research to identify
the utility of each of these modalities in the modern management of Hodgkin’s Lymphoma. This article will provide a critical
review of the developments and indications for modern radiotherapy, in context with advances in chemotherapy, for the treatment
of Hodgkin’s Lymphoma.
1.Introduction
During the ﬁrst half of the 20th century, Hodgkin’s Lym-
phoma(HL)wasincurableuntilthedevelopmentofeﬀective
therapeutic radiation [1]. It involved irradiating beyond
the site of disease to include the adjacent nodal groups,
the so-called extended ﬁeld radiotherapy (EFRT) with total
or subtotal nodal irradiation [2]. With Radiotherapy (RT)
alone, 10-year relapse-free survival of around 70% had been
achieved in early-staged HL [3, 4].
However, advanced stage HL remained less curable
with RT even with subtotal or total nodal RT until the
introductionofcombinationchemotherapy.Withtheadvent
of eﬀective chemotherapy regimes in the 1980s with MOPP
[5] and ABVD [6], better cure rates were achieved in
advanced disease establishing chemotherapy as the main line
of treatment in advanced disease. Gradually, chemotherapy
use moved to earlier-stage disease, initially as a pre-RT
treatment in bulky mediastinal cases to reduce the extent
of mediastinal RT and later to improve the outcome of RT
alone. With emerging reports of long-term toxicities from
EFRT, namely with pulmonary, cardiac toxicity, and sec-
ondary malignancies [7–13] together with studies showing
that limited RT was suﬃcient after prior chemotherapy,
combined modality treatment has been established in early
disease.Morerecently,therehasbeenseveralopinionscalling
on treating early stage HL with chemotherapy alone without
RT, and this remains an interesting research question.
The paper below will aim to highlight the developments
of RT in HL treatment, with speciﬁc focus on its role in early,
advanced, and relapsed disease.
2.Developments inRT
2.1. Background. The concept of RT to cure HL by Gilbert
[14] was implemented with kilovoltage [15] and later
with megavoltage machines [1]. Doses of up to 4500rads
(1000rads/wk) were commonly used to treat extended ﬁelds
in order to achieve total lymphoid irradiation (TLI). This
included mantle ﬁeld, inverted-Y techniques, and modiﬁca-
tions to include splenic irradiation, delivered with a parallel
opposed technique. It was also not uncommon to irradiate
liver and lungs involved with disease; all this was done when
staging laparotomy and splenectomy were standard practice.
In the light of RT toxicities, suboptimal relapse and
survival rates together with the introduction of eﬀective
chemotherapy,theimpetustorationaliseRTdeliverybecame2 Advances in Hematology
a priority. This was achieved through prognostic risk strat-
iﬁcation, combined modality approach with chemotherapy
in concert with advances in RT. These include improvements
withRTtechniquesandrationalisation inboththeirradiated
volume as well as the RT doses used.
Risk stratiﬁcation was introduced in the 1980s originally
by the BNLI group [16], and also the EORTC and GHSG
groups to rationalise treatment for good prognostic-HL
patients in order to minimise toxicity. The EORTC/GELA
and GHSG groups have identiﬁed several features indicative
of unfavourable prognosis [17, 18]( Table 1) in early stage
HL which has allowed studies to investigate risk stratiﬁed
treatment.
Advanced disease is classiﬁed as stage 3 and 4 disease
and also includes stage 2B disease in presence of bulky
mediastinal or extranodal disease in the GHSG classiﬁcation.
2.2. RT Doses. From the traditional doses of over 40–
45Gy used, doses for treatment of HL have been rationally
reduced in order to maintain optimal outcome with reduced
toxicities. Doses of 30Gy have been shown to yield similar
results to higher doses used with no increased dose-response
relationship seen for higher doses used [19–21], and as
such 30Gy in combined modality treatment (CMT) has
become the standard in most countries. Lower doses have
also been shown to be eﬀective from 2 current studies, one
by the EORTC/GELA group and the other the GHSG group.
The ongoing EORTC/GELA H9F trial had 20Gy Involved
Field RT (IFRT) in one trial arm which showed similar
resultstohigherdosesofradiotherapyincombinedmodality
treatment of early-staged HL [22]. Incidentally, the arm
whereRTwasomittedhasbeenstoppedduetohigherrelapse
rates found. Preliminary results from the ongoing GHSG
HD10 trial has shown that dose reduction to 20GyIFRT
as part of combined modality treatment showed equivalent
results to higher doses [23].
2.3. RT Volume. As well as the ongoing reduction in RT
doses being used, smaller RT ﬁelds have been used and
several randomised trials have shown that IFRT, where only
the nodal region is irradiated, is as eﬀective as EFRT with
equivalent overall survival rates [24–27]. Further progress
has gone beyond the concept of IFRT to Involved Site RT
(ISRT) and now Involved Node RT (INRT), where only the
involved nodes are irradiated, have been proposed by the
EORTC/GELA group [28]. Encouraging results have come
from a retrospective series showing equivalent progression-
free survival (PFS) and overall survival (OS) for INRT
compared to IFRT [29].
2.4. RT Technology. In concert with the above developments,
there has been signiﬁcant improvement in RT techniques
in order to achieve more conformal radiotherapy treatment
from the traditional large parallel opposed ﬁelds used. This
has allowed RT to progress to 2D conformal [30]a n dt o
now commonly used 3D conformal techniques [31], with
Intensity-modulated RT (IMRT) being shown to be able to
further improve target volume conformity with reductions
of dose to critical structures [32]. These have therefore
allowed the developments of reduction in irradiated volume
as described above.
3. Role of RT in EarlyDisease
The improvement of clinical staging with the introduction
of the Cotswolds modiﬁcations of the Ann Arbour staging
in 1989 [33] together with adverse outcomes being reported
with the routine use of staging laparotomy and splenectomy
with no clinical beneﬁt [16] led to recommendations to
abandon these procedures. Clinical risk stratiﬁcation iden-
tifying favourable and unfavourable groups within early-
staged HL by groups such as the EORTC and GHSG has
allowed investigation to rationalise treatment in early HL
further.
ResultsfromseveraltrialssupportCMTforthetreatment
of early-staged HL.
Studies comparing CMT with RT alone have shown
superiority of CMT. These have been shown by both the
GHSGandEORTCgroups.IntheEORTCH8Ftrial,patients
with early-staged favourable HL were randomised to either
3 cycles of MOPP/ABV chemotherapy followed by IFRT of
36Gy or to RT alone with STNI. The results showed a better
event-free survival (EFS) and OS in favour of the CMT arm
(EFS98%versus74%,10yrOS97%versus92%)[26].These
results are supported by the GHSG HD7 trial favouring 2
cycles of ABVD chemotherapy followed by RT versus RT
alone in early-staged favourable HL [34].
Studies comparing CMT with chemotherapy alone have
shown that chemotherapy alone yields worse outcomes. The
EORTC/GELA H9F trial compared 6 cycles of chemotherapy
with or without IFRT [22]. The arm without RT was closed
early due to higher-than-expected relapse rates. Similar
ﬁndings were reported in the CCG 5942 trial comparing 4–6
cyclesofchemotherapywithorwithoutRT.Thearmwithout
RT was closed early due to a signiﬁcantly higher number
of relapses seen on the no-radiotherapy arm [35]. Two
North American studies comparing chemotherapy alone
versus CMT showed an inferior PFS and freedom from
progression (FFP) in the chemotherapy alone arms with the
NCIC/ECOGHD-6Trialshowinga5-YearPFSof87%versus
93%, in favour of CMT [36] and the MSKCC trial showing a
FFP of 86% versus 81% [37]i nf a v o u ro fC M T .A d v a n t a g e s
inoverallsurvivalforCMTwereshownintheTataMemorial
Trial which showed an 8 year EFS of 88% versus 76% and
OS of 100% versus 89% in favour of CMT versus 6 cycles of
ABVD alone [38]. Although all stages of HL were included in
this trial, 55% of enrolled patients had early HL.
Based on these results and data supporting ABVD
over other combination chemotherapy regimes [39–42], the
recommendations for the treatment of early HL are with the
combined modality approach with 2 to 4 cycles of ABVD
followed by IFRT of 30Gy [43, 44] with the ESMO group
making further recommendations that favourable early HL
patients should receive 2 cycles of ABVD in combination
withIFRTwhilst4cyclesofABVDincombinationwithIFRT
being reserved for the unfavourable group. Further dose de-
escalation studies for favourable early HL are underway suchAdvances in Hematology 3
Table 1: EORTC/GELA and GHSG risk factors for early-staged HL.
Early-staged (I-II) unfavourable features (EORTC/GELA) Early-staged (I-II) unfavourable features (GHSG)
Four or more nodal areas involved Three or more nodal areas involved
Bulky mediastinum∗ Bulky mediastinum∗
ESR >5 0w i t h o u tBs y m p t o m so r>30 with B symptoms ESR >5 0w i t h o u tBs y m p t o m so r>30 with B symptoms
Aged 50 years old or more Extranodal disease
∗Bulky mediastinum deﬁned as mediastinal/thoracic ratio >0.35.
as the NCRN RAPID trial in the UK using information from
interval PET imaging. The prognostic information from
interval PET scanning in HL [45] has also formed the basis
for the GHSG HD16 trial and EORTC 10F trial. The use
of PET imaging is also now becoming standard for routine
staging of HL [46] as well as gaining support for use in RT
planning with INRT [47].
Some controversy has arisen over the proposition for
the use of chemotherapy alone in the management of early
HL [48–50] lending support for this approach to be within
an option of the NCCN guidelines for the management of
e a r l yH L[ 51]. The impetus for this approach was based on
toxicity data during the era where EFRT was routine. There
remains no evidence to support this approach with worse
reported outcomes when RT is omitted, as highlighted from
the various studies discussed earlier. A recent meta-analysis
studying 5 randomised control trials [52] has conﬁrmed the
superiority of CMT over chemotherapy alone with a hazard
r a t i o( H R )o f0 . 4 1f o rt u m o u rc o n t r o la n d0 . 4 0f o rO Sf o r
patients receiving CMT compared to chemotherapy alone.
As such the standard of care for early HL remains CMT.
A caveat for radical treatment with radiotherapy alone
is with Nodular Lymphocyte Predominant Hodgkin’s Lym-
phoma (NLPHL) where 30Gy has been shown to yield
similar results compared with combined-modality treatment
for Stage 1A NLPHL with no risk factors whilst advanced
NLPHL has been treated with classic HL protocols [53, 54].
4.Role ofRTinAdvancedDisease
In the prechemotherapy era, advanced HL was treated with
Total Lymph Node Irradiation (TLI) where the majority
of patients relapsed and died. With the advent of MOPP,
long term remission of around 50% were achieved [55].
This was then replaced by ABVD after randomised trials
showed superiority over other regimes including MOPP
[56, 57]. Several other regimes have also been shown to
be more toxic but no more eﬀective than ABVD [39–42,
58] with 3-year OS survival rates of around 90% being
achieved. Based on these ﬁndings, ABVD has now become
the standard arm for comparison in ongoing trials. But with
suboptimal long-term failure-free and survival rates, dose
escalated regimes have been used to improve results [59],
however not without increased toxicities. Direct comparison
of escalated BEACOPP with the standard ABVD regime is
ongoing with the EORTC 20012 trial.
T h eS t a n f o r dVp r o t o c o lo ﬀered an alternative regime
with a short period of 12 weeks of chemotherapy followed by
RT to bulky sites, classiﬁed as 5cm or more [60]. However,
comparison of the Stanford V regime with ABVD and
MOPPEBVCAD showed worse PFS [61]. Results are awaited
for the UK NCRI Stanford V versus ABVD trial for advanced
HL.
Oﬀering RT after eﬀective chemotherapy is not standard
practice and is still undergoing investigation. However,
data so far can allow risk stratiﬁcation into groups whom
may beneﬁt. Although a meta-analysis [62] and studies
by the GELA [63]a n dE O R T Cg r o u p s[ 64] showed no
beneﬁtofconsolidationRTaftereﬀectivechemotherapywith
suggestions of worsened outcome when RT was added, more
recent data have emerged from 2 large randomised control
trials(RCT)insupportofconsolidationRT.TheUKLGLY09
trial showed 5 year PFS of 71% versus 86%, with OS HR of
0.47 in favour of consolidation RT [65]. This concurs with
another large RCT from Tata Memorial Hospital showing
EFS and OS advantage for consolidation RT after 6 cycles of
ABVD chemotherapy in all stages of HL [38]. Furthermore,
most of the trials of chemotherapy dose escalation include
RT for most patients in their protocols. Utilising the extra
data obtained from PET to identify metabolically active
residual masses postchemotherapy, the GHSG HD15 trial
incorporates PET to assess residual lesions >2.5cm to receive
consolidation RT, and preliminary results have been able to
show favourable negative predictive value of PET of 94%
[66]h e n c eo ﬀering the potential towards a risk stratiﬁed
approach.
5. Role of RT in SalvageTreatment
Although the standard treatment for patients with refractory
and relapsed HL to chemotherapy and combined chemo-
radiotherapy is high-dose therapy supported by autologous
stem-cell transplant, RT has a role in the peritransplantation
setting. Results by Poen et al. at Stanford [67] has shown
that most relapses occurred in areas of known disease
pretransplant and posttransplant irradiation resulted in no
in-ﬁeld relapses. This concept has been supported by a series
at MSK showing favourable results [68, 69]. Results from
clinical trials in this setting as well as studies looking at the
utility of PET to identify peritransplant active disease should
yield exciting recommendations.
6. Conclusion
From the above review, it can be seen that the role of
RT in the management of HL has changed considerably4 Advances in Hematology
over the last century with the advent of better staging, risk
stratiﬁcation strategies, eﬀective chemotherapy and salvage
regimens, and the progress in RT techniques and technology.
RT doses and volume have been signiﬁcantly rationalised
to minimise toxicities with the establishment of highly
conformal RT techniques whilst allowing concepts such as
INRT to be introduced.
It is important to highlight that studies which have
shown toxicities with RT have been based on historical
series where obsolete nonconformal RT with higher doses
were used and that survival data reported in trials may
be misrepresented with the prevalence and success rates
of salvage chemotherapy regimes and transplantation in
relapsed HL.
In early-staged HL, CMT is thus the established standard
of care with adjustments in the number of chemotherapy
cycles justiﬁed according to the risk factors. In advanced-
stagedHL,afullcourseofchemotherapyisthestandardwith
special circumstances advocating consolidation RT, namely
initial bulk disease or residual PET avidity. Ongoing trials
will no doubt clarify the role of RT in these situations as well
as identifying the role of PET to dictate consolidation RT.
Ongoing work with the above strategies of achieving
long-term cure whilst minimising toxicities, whether it be
from radiotherapy or chemotherapy, should continue to
yield promising results.
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